You just read:

MEI Pharma Presents Clinical Data from Ongoing Phase 1b Study of ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Hematology Annual Meeting

News provided by

MEI Pharma, Inc.

Dec 02, 2018, 12:00 ET